ALEXANDER T. ROSS, M.D.; VIRGINIA JACKSON
This content is PDF only. Please click on the PDF icon to access.
Reports on the effectiveness of sodium diphenyl hydantoinate (dilantin sodium) in epilepsy have accumulated rapidly since Merritt and Putnam1 inaugurated the use of the drug in 1938. Naturally most interest has devolved upon its use in the control of convulsions and upon its toxic effects—rash, anorexia, nausea, vomiting, ataxia, gingivitis,2 and to a less extent delusions, hallucinations, prolonged confusion, agitation, depression, irritability, and suspiciousness.3, 4 The toxic effects apparently are manifested earlier, more frequently, and more severely in patients over 40 years of age, and consequently the drug would seem to be of less danger in younger and better preserved
ROSS AT, JACKSON V. DILANTIN SODIUM: ITS INFLUENCE ON CONDUCT AND ON PSYCHOMETRIC RATINGS OF INSTITUTIONALIZED EPILEPTICS1. Ann Intern Med. 1940;14:770–773. doi: 10.7326/0003-4819-14-5-770
Download citation file:
Published: Ann Intern Med. 1940;14(5):770-773.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use